OOIR: Observatory of International Research

Papers

(The TQCC of Cancer Treatment Reviews is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook	544
Review of precision cancer medicine: Evolution of the treatment paradigm	323
Immunotherapy for pancreatic cancer: A 2020 update	257
Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysis	184
MYC as a target for cancer treatment	168
The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target	166
KRAS: From undruggable to a druggable Cancer Target	130
How did lomustine become standard of care in recurrent glioblastoma?	119
Adenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies	111
MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma	89
Microsatellite instability in Gastric Cancer: Between lights and shadows	88
The role of autophagy in resistance to targeted therapies	88
Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer	87
Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality	85
BAP1: Not just a BRCA1-associated protein	84
Targeting FGFR inhibition in cholangiocarcinoma	84
MEK inhibitor resistance mechanisms and recent developments in combination trials	83
The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal	81
Treatment landscape of metastatic pancreatic cancer	81
KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures	80
Cancer and COVID-19: Unmasking their ties	76
Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer	75
EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins	74
Global challenges and policy solutions in breast cancer control	74
Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities	72

HER2-positive advanced breast cancer treatment in 2020	70
Challenges in the treatment of gastric cancer in the older patient	70
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy	65
Targeting ARID1A mutations in cancer	65
The role of exosomes in metastasis and progression of melanoma	63
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives	60
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—Focus on proactive monitoring, diagnosis, and management	59
Evolving role of regorafenib for the treatment of advanced cancers	59
SARS-CoV-2 and cancer: Are they really partners in crime?	58
Impact of high tumor mutational burden in solid tumors and challenges for biomarker application	56
NRAS mutant melanoma: Towards better therapies	56
Immunotherapy in non-small cell lung cancer harbouring driver mutations	55
Parathyroid cancer: An update	52
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping	51
Melanoma brain metastases – Interdisciplinary management recommendations 2020	50
Thymic epithelial tumors: From biology to treatment	47
Targeting brain metastases in breast cancer	46
Sarcomas: Immune biomarker expression and checkpoint inhibitor trials	45
Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis	45
Targeting HER2 heterogeneity in breast cancer	44
Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives	44
Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic	43
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials	43
Roadmap to cure multiple myeloma	43
The force of HER2 – A druggable target in NSCLC?	42
Liquid biopsy in lymphoma: Molecular methods and clinical applications	41
Turning tumors from cold to inflamed to improve immunotherapy response	41
Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis	41
Cabozantinib: An evolving therapy for hepatocellular carcinoma	40
Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis	40
Treatment strategies for patients with diffuse large B-cell lymphoma	40
Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression	39
Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published data	38
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges	38
A basic review on systemic treatment options in WHO grade II-III gliomas	38
KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond	37
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors	37
Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials	36
Blood biomarkers for differential diagnosis and early detection of pancreatic cancer	36
The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives	34
Neurological complications of cancer immunotherapy	34
Precision medicine in breast cancer: From clinical trials to clinical practice	34
Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis	33
Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone	33
Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer	33
Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?	33
Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives	32
Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials	31
A review of retroperitoneal liposarcoma genomics	31
Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice	30

Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities	30
Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review	30
Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus	30
Systematic review of real-world studies evaluating the impact of medication non-adherence to endocrine therapies on hard clinical endpoints in patients with non-metastatic breast cancer	29
Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN)	29
Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis	29
The safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (Hepatitis B/C, HIV): A review of the available evidence	29
Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes	28
Radiomics and radiogenomics in head and neck squamous cell carcinoma: Potential contribution to patient management and challenges	28
Current management of stage IV nasopharyngeal carcinoma without distant metastasis	28
Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities	28
SELNET clinical practice guidelines for soft tissue sarcoma and GIST	28
Immune checkpoint Inhibitor–Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis	28
The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines	28
Accelerating drug development in breast cancer: New frontiers for ER inhibition	28
A comprehensive overview of tumour deposits in colorectal cancer: Towards a next TNM classification	27
Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications	27
Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer	27
Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near future	27
The promise of bispecific antibodies: Clinical applications and challenges	27
Immunotherapy in cervix cancer	27
Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials	27
Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines)	27
Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era	26
Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors	25
CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer	25
Cellular immunotherapy in breast cancer: The quest for consistent biomarkers	25
First line treatment of BRAF mutated advanced melanoma: Does one size fit all?	25
Seroprevalence of SARS-CoV-2–specific antibodies in cancer outpatients in Madrid (Spain): A single center, prospective, cohort study and a review of available data	24
PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations	23
Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation	23
Prognostic factors in patients with oligometastatic breast cancer – A systematic review	23
The current clinical landscape of personalized cancer vaccines	23
Newly diagnosed ovarian cancer: Which first-line treatment?	22
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis	22
Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review	21
Artificial intelligence for prediction of treatment outcomes in breast cancer: Systematic review of design, reporting standards, and bias	21
Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?	21
Clinical trial data of Anti–PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: A review	21
The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas	21
New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis	20
Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours	20
Clinical development of IDH1 inhibitors for cancer therapy	20
Comparing cancer and cardiovascular disease trends in 20 middle- or high-income countries 2000–19: A pointer to national trajectories towards achieving Sustainable Development goal target 3.4	20
ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias	20
Recent advancements of antiangiogenic combination therapies in ovarian cancer	20
Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment	20